Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil

2023; Elsevier BV; Volume: 35; Linguagem: Inglês

10.1016/j.ctarc.2023.100683

ISSN

2468-2942

Autores

Marcello Moro Queiroz, Karina Perez Sacardo, Mauricio Fernando Ribeiro, Luiza Lara Gadotti, Rodrigo Saddi, Leandro Jonata de Carvalho Oliveira, Rudinei Diogo Marques Linck, Marcelo Cruz, Romualdo Barroso‐Sousa, Marina Sahade, Tatiana Strava Corrêa, Max S. Mano, Daniele Xavier Assad, Andrea Kazumi Shimada, Artur Katz,

Tópico(s)

Chronic Lymphocytic Leukemia Research

Resumo

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have been recently developed and introduced into clinical practice. We retrospectively analyzed data from patients with confirmed HR+/HER2 metastatic breast cancer treated with hormonal therapy in combination with ribociclib (R), palbociclib (P), or abemaciclib (A). Outcomes: median progression-free survival (mPFS), time to treatment discontinuation (mTTD), and objective response rate (ORR). Between January 2016 - June 2021, 142 patients were treated with an CDK4/6i (79 P, 42 R, 21 A). The median age was 59 years and 67.6% had recurrent disease. Roughly 35.2%, 36.6%, 28.2% of the patients had 1, 2 or 3+ metastatic sites, respectively, and 55.6% of the patients received CDK4/6i as a first-line treatment. The mPFS was 28m(R) vs. 14m(P) vs. 6m(A) (P = 0.002), with a higher proportion of patients receiving R in the first-line setting. However, no difference was seen when the analysis was restricted to the first-line scenario (P = 0.193). Sixty-four patients required one dose reduction, and 19 patients required two. ORR was 76.2% (R) vs 62% (P) vs 42.9% (A). More patients achieved a complete response with R and P, with no difference in the incidence of partial response and stable disease. Adverse events occurred in 94.4% of the population, with the most common grade 3–4 AE being neutropenia (59.1%). Our results confirm the efficacy and tolerability of CDK4/6i in routine clinical practice. This is the first real-world data describing and comparing the efficacy and toxicity of CDK4/6i in the Brazilian population.

Referência(s)